Edition:
United States

Aveo Pharmaceuticals Inc (AVEO.O)

AVEO.O on Consolidated Issue listed on NASDAQ Capital Market

0.60USD
27 Apr 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.60
Open
$0.59
Day's High
$0.61
Day's Low
$0.59
Volume
47,364
Avg. Vol
459,589
52-wk High
$1.15
52-wk Low
$0.50

Latest Key Developments (Source: Significant Developments)

Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues
Thursday, 13 Apr 2017 08:00am EDT 

Aveo Pharmaceuticals Inc : Aveo announces submission of response to tivozanib marketing authorization application day 180 list of outstanding issues .Aveo Pharma - EUSA remains tentatively scheduled to provide oral explanation to EMA's committee for medicinal products for human use at May 2017 meeting.  Full Article

Aveo Pharmaceuticals says cash on hand would fund planned operations into Q2 2018
Wednesday, 5 Apr 2017 07:02am EDT 

Aveo Pharmaceuticals Inc :Aveo pharmaceuticals - "cash on hand would fund planned operations into 2Q 2018; beyond tivo-3 readout which is expected 1Q 2018" - sec filing.  Full Article

Aveo announces pricing of $15 mln public offering of common stock
Tuesday, 28 Mar 2017 09:09am EDT 

Aveo Pharmaceuticals Inc : Aveo announces pricing of $15.0 million public offering of common stock .Says public offering of 30.0 million common shares priced at $0.50per share.  Full Article

Aveo announces proposed offering of common stock
Tuesday, 28 Mar 2017 06:33am EDT 

Aveo Pharmaceuticals Inc : Aveo announces proposed offering of common stock .Aveo Pharmaceuticals- offering's proceeds to be used in development, pre-commercial expenses incurred for ongoing phase 3 clinical trial of tivozanib.  Full Article

Aveo Pharmaceuticals says doubts ability to continue as a going concern - SEC filing
Wednesday, 22 Mar 2017 04:35pm EDT 

Aveo Pharmaceuticals Inc : Aveo Pharmaceuticals says have identified conditions and events that raise substantial doubt about ability to continue as a going concern - SEC filing . Aveo Pharmaceuticals says "continue as a going concern, we must secure additional capital to provide us with additional liquidity" . Aveo Pharma - believe about $23.3 million in existing cash,cash equivalents, securities at Dec. 31, 2016, could allow to fund planned operations into Q4 2017 .Aveo Pharmaceuticals Inc says additional funds will be needed to extend planned operations into 2018.  Full Article

Aveo reports full year 2016 financial results
Wednesday, 22 Mar 2017 04:05pm EDT 

Aveo Pharmaceuticals Inc - : Aveo reports full year 2016 financial results and provides business update . Aveo Pharmaceuticals - $23.3 million in cash,cash equivalents,marketable securities as of Dec 31, 2016 could allow co to fund planned operations into q4 2017 .Qtrly loss per share $0.07.  Full Article

Aveo announces first patient dosed in phase 1/2 tinivo trial
Wednesday, 22 Mar 2017 07:00am EDT 

Aveo Pharmaceuticals Inc : Aveo announces first patient dosed in phase 1/2 tinivo trial of tivozanib and opdivo (nivolumab) in advanced RCC . Aveo Pharmaceuticals Inc - phase 1 trial will evaluate safety of tivozanib in combination with nivolumab at escalating doses of tivozanib .Aveo Pharmaceuticals Inc - look forward to initial results from phase 1 portion of tinivo trial in first half of 2017.  Full Article

Aveo reports clinical and regulatory updates for tivozanib
Thursday, 9 Feb 2017 04:05pm EST 

Aveo Pharmaceuticals Inc : Aveo announces clinical and regulatory updates for tivozanib . Aveo Pharmaceuticals Inc- phase 1/2 tinivo trial sites scheduled to open for enrollment in early march . Aveo Pharmaceuticals Inc- partner Eusa Pharma receives day 180 list of outstanding issues from EMA, oral explanation expected in 2q 2017 . Aveo Pharmaceuticals Inc- pivotal tivo-3 trial enrollment proceeding substantially ahead of schedule; enrollment completion expected in June .Aveo Pharmaceuticals Inc- initial results from opdivo(reg) combination tinivo study expected in RCC in first half of 2017.  Full Article

Aveo Oncology Q3 loss per share $0.07
Friday, 4 Nov 2016 07:00am EDT 

Aveo Pharmaceuticals Inc : Says believe that $30.8 million in cash resources could allow to fund planned operations into Q4 of 2017 . Aveo Pharma -expect approval decision in first-line renal cell cancer in europe, initial results from opdivo(reg) combination tinivo study in h1 2017 . Sees top-line data from U.S.-registration-directed phase 3 tivo-3 study in renal cell cancer in q1 of 2018 . Aveo oncology reports third quarter 2016 financial results and provides business update .Q3 loss per share $0.07.  Full Article

Aveo initiates evaluation of Tivozanib in combination with Bristol-Myers Squibb's opdivo in advanced renal cell carcinoma
Monday, 15 Aug 2016 07:00am EDT 

Aveo : Initiates Evaluation Of Tivozanib In Combination With Bristol Myers Squibb's Opdivo® (nivolumab) in advanced renal cell carcinoma .Phase 1/2 tinivo trial to commence at institut gustave roussy in paris.  Full Article

More From Around the Web

BRIEF-Aveo announces submission of response to Tivozanib marketing authorization application day 180 list of outstanding issues

* Aveo announces submission of response to tivozanib marketing authorization application day 180 list of outstanding issues